RS62368B1 - Lečenje postbarijatrijske hipoglikemije eksendinom(9-39) - Google Patents

Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)

Info

Publication number
RS62368B1
RS62368B1 RS20211073A RSP20211073A RS62368B1 RS 62368 B1 RS62368 B1 RS 62368B1 RS 20211073 A RS20211073 A RS 20211073A RS P20211073 A RSP20211073 A RS P20211073A RS 62368 B1 RS62368 B1 RS 62368B1
Authority
RS
Serbia
Prior art keywords
exendin
post
treatment
bariatric hypoglycemia
bariatric
Prior art date
Application number
RS20211073A
Other languages
English (en)
Inventor
Tracey L Mclaughlin
Colleen M Craig
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of RS62368B1 publication Critical patent/RS62368B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20211073A 2015-05-22 2016-05-23 Lečenje postbarijatrijske hipoglikemije eksendinom(9-39) RS62368B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29
PCT/US2016/033837 WO2016191395A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with exendin(9-39)
EP16800621.1A EP3297654B1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number Publication Date
RS62368B1 true RS62368B1 (sr) 2021-10-29

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20211073A RS62368B1 (sr) 2015-05-22 2016-05-23 Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
RS20211458A RS62627B1 (sr) 2015-05-22 2016-05-23 Tretman post-bariatrijske hipoglikemije sa glp-1 antagonistima

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20211458A RS62627B1 (sr) 2015-05-22 2016-05-23 Tretman post-bariatrijske hipoglikemije sa glp-1 antagonistima

Country Status (17)

Country Link
US (8) US10639354B2 (sr)
EP (4) EP3297654B1 (sr)
AU (4) AU2016267052B2 (sr)
BR (2) BR112017024997A2 (sr)
CA (2) CA3024358A1 (sr)
CL (2) CL2017002911A1 (sr)
CY (2) CY1124616T1 (sr)
DK (2) DK3297653T3 (sr)
ES (2) ES2887723T3 (sr)
HR (2) HRP20211285T1 (sr)
HU (2) HUE055728T2 (sr)
LT (2) LT3297653T (sr)
PL (2) PL3297653T3 (sr)
PT (2) PT3297653T (sr)
RS (2) RS62368B1 (sr)
SI (2) SI3297654T1 (sr)
WO (2) WO2016191394A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2710948T3 (es) 2007-01-08 2019-04-29 Univ Pennsylvania Composiciones y usos médicos de las mismas
PL3297653T3 (pl) 2015-05-22 2022-01-31 The Board Of Trustees Of The Leland Stanford Junior University Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
US20210030847A1 (en) * 2018-01-23 2021-02-04 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
EP3867266A4 (en) * 2018-10-15 2022-07-13 Eiger Biopharmaceuticals, Inc. AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA
WO2020144378A1 (en) * 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
DE69900026T2 (de) 1998-01-30 2001-05-10 Novo Nordisk As Eine injektionsspritze
BR9916965A (pt) 1998-12-10 2001-11-06 Agouron Pharma Compostos antagonistas de receptores não peptìdicos de glp-1, seus derivados, composto útil derivado dos mesmos, composição farmacêutica, método para regular a secreção de insulina em mamìferos, método de inibição da atividade de glp-1, método de inibição da ligação de glp-1 ao receptor de glp-1 e método de inibição da ativação do receptor de glp-1
ES2343072T3 (es) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. Exendina para la supresion del glucagon.
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
ATE531374T1 (de) 2004-04-15 2011-11-15 Alkermes Inc Vorrichtung auf polymerbasis mit verzögerter freisetzung
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
MX2008002370A (es) 2005-08-19 2008-04-29 Amylin Pharmaceuticals Inc Exendina para tratar la diabetes y reducir el peso del cuerpo.
EA200870575A1 (ru) 2006-05-26 2009-08-28 Амилин Фармасьютикалз, Инк. Композиции и способы лечения застойной сердечной недостаточности
ES2710948T3 (es) 2007-01-08 2019-04-29 Univ Pennsylvania Composiciones y usos médicos de las mismas
ATE516834T1 (de) 2007-04-05 2011-08-15 Tecpharma Licensing Ag Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
ES2645588T3 (es) 2008-05-05 2017-12-05 Oramed Ltd. Métodos y composiciones para la administración oral de exenatida
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
WO2010003939A1 (en) * 2008-07-08 2010-01-14 Novartis Ag Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
MY183275A (en) 2009-04-03 2021-02-18 Nestec Sa Improvement in promotion of healthy catch-up growth
ES2705249T3 (es) 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2768856A4 (en) 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
US20150005233A1 (en) 2012-02-08 2015-01-01 Seneb Biosciences, Inc. Treatment of hypoglycemia
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PL3297653T3 (pl) 2015-05-22 2022-01-31 The Board Of Trustees Of The Leland Stanford Junior University Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂

Also Published As

Publication number Publication date
US20180117122A1 (en) 2018-05-03
US20180147261A1 (en) 2018-05-31
US20230346890A1 (en) 2023-11-02
HRP20211768T1 (hr) 2022-02-18
US20200276272A1 (en) 2020-09-03
BR112017025000A2 (pt) 2018-08-07
EP3936143A1 (en) 2022-01-12
PT3297654T (pt) 2021-09-06
AU2016267057B2 (en) 2021-12-23
WO2016191394A1 (en) 2016-12-01
EP3297653B1 (en) 2021-09-15
BR112017024997A2 (pt) 2018-07-31
EP3297653A4 (en) 2018-12-26
HUE055728T2 (hu) 2021-12-28
EP3297654A1 (en) 2018-03-28
AU2016267057A1 (en) 2017-12-14
EP3978011A1 (en) 2022-04-06
PL3297653T3 (pl) 2022-01-31
RS62627B1 (sr) 2021-12-31
CY1125147T1 (el) 2023-03-24
US20200276271A1 (en) 2020-09-03
LT3297654T (lt) 2021-10-25
US20210315974A1 (en) 2021-10-14
CA3024353A1 (en) 2016-12-01
EP3297654B1 (en) 2021-07-07
CA3024358A1 (en) 2016-12-01
AU2016267052B2 (en) 2022-01-20
SI3297654T1 (sl) 2021-11-30
US10993992B2 (en) 2021-05-04
US11622995B2 (en) 2023-04-11
US10993991B2 (en) 2021-05-04
AU2016267052A1 (en) 2017-12-14
ES2897955T3 (es) 2022-03-03
EP3297653A1 (en) 2018-03-28
SI3297653T1 (sl) 2022-01-31
ES2887723T3 (es) 2021-12-27
US20240000894A1 (en) 2024-01-04
US10660937B2 (en) 2020-05-26
DK3297653T3 (da) 2021-10-18
US10639354B2 (en) 2020-05-05
HUE057301T2 (hu) 2022-05-28
CL2017002913A1 (es) 2018-06-01
CY1124616T1 (el) 2022-07-22
CL2017002911A1 (es) 2018-05-25
DK3297654T3 (da) 2021-09-06
AU2022202506A1 (en) 2022-05-12
US11617782B2 (en) 2023-04-04
EP3297654A4 (en) 2018-04-11
WO2016191395A1 (en) 2016-12-01
LT3297653T (lt) 2022-01-10
PT3297653T (pt) 2021-10-25
US20210290731A1 (en) 2021-09-23
AU2022201973A1 (en) 2022-04-14
PL3297654T3 (pl) 2021-12-20
HRP20211285T1 (hr) 2022-01-07

Similar Documents

Publication Publication Date Title
LT3297654T (lt) Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39)
SG10202100803WA (en) Endoscope with pannable camera and related method
HK1248552A1 (zh) 使用川地匹坦的治療方法
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
HK1256423A1 (zh) 纖維化治療
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
HK1232071A1 (zh) 使用 抑制劑治療 感染
RS60316B1 (sr) Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
GB201414366D0 (en) Blood defence
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201503008D0 (en) Treatment
AU2015904246A0 (en) Treatment of diabetes
AU2016901862A0 (en) Treatment of diabetes
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201518349D0 (en) Treatment
GB201513922D0 (en) Treatment of hyperpigmentation
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
AU2015902668A0 (en) Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en) Agent for treating diabetes
GB201407396D0 (en) Confectionary treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes